Search

Your search keyword '"Puissant, Alexandre"' showing total 398 results
Start Over Author "Puissant, Alexandre"
398 results on '"Puissant, Alexandre"'

1. Targeting a lineage-specific PI3Kɣ–Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule

Author

Kelly, Lois M., Rutter, Justine C., Lin, Kevin H., Ling, Frank, Duchmann, Matthieu, Latour, Emmanuelle, Arang, Nadia, Pasquer, Hélène, Ho Nhat, Duong, Charles, Juliette, Killarney, Shane T., Ang, Hazel X., Namor, Federica, Culeux, Cécile, Lombard, Bérangère, Loew, Damarys, Swaney, Danielle L., Krogan, Nevan J., Brunel, Luc, Carretero, Élodie, Verdié, Pascal, Amblard, Muriel, Fodil, Sofiane, Huynh, Tony, Sebert, Marie, Adès, Lionel, Raffoux, Emmanuel, Fenouille, Nina, Itzykson, Raphaël, Lobry, Camille, Benajiba, Lina, Forget, Antoine, Martin, Anthony R., Wood, Kris C., and Puissant, Alexandre

Published
2024
Full Text
View/download PDF

2. Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium

Author

Pikman, Yana, Tasian, Sarah K, Sulis, Maria Luisa, Stevenson, Kristen, Blonquist, Traci M, Apsel Winger, Beth, Cooper, Todd M, Pauly, Melinda, Maloney, Kelly W, Burke, Michael J, Brown, Patrick A, Gossai, Nathan, McNeer, Jennifer L, Shukla, Neerav N, Cole, Peter D, Kahn, Justine M, Chen, Jing, Barth, Matthew J, Magee, Jeffrey A, Gennarini, Lisa, Adhav, Asmani A, Clinton, Catherine M, Ocasio-Martinez, Nicole, Gotti, Giacomo, Li, Yuting, Lin, Shan, Imamovic, Alma, Tognon, Cristina E, Patel, Tasleema, Faust, Haley L, Contreras, Cristina F, Cremer, Anjali, Cortopassi, Wilian A, Garrido Ruiz, Diego, Jacobson, Matthew P, Dharia, Neekesh V, Su, Angela, Robichaud, Amanda L, Saur Conway, Amy, Tarlock, Katherine, Stieglitz, Elliot, Place, Andrew E, Puissant, Alexandre, Hunger, Stephen P, Kim, Annette S, Lindeman, Neal I, Gore, Lia, Janeway, Katherine A, Silverman, Lewis B, Tyner, Jeffrey W, Harris, Marian H, Loh, Mignon L, and Stegmaier, Kimberly

Subjects
Cancer, Rare Diseases, Human Genome, Genetics, Clinical Trials and Supportive Activities, Orphan Drug, Biotechnology, Hematology, Clinical Research, Pediatric Cancer, Childhood Leukemia, Pediatric, Development of treatments and therapeutic interventions, Aetiology, 5.1 Pharmaceuticals, 2.1 Biological and endogenous factors, Good Health and Well Being, Biomarkers, Tumor, Child, Cohort Studies, Disease Progression, Feasibility Studies, Female, Humans, Leukemia, Male, Molecular Targeted Therapy, Neoplasm Recurrence, Local, Prospective Studies, United States, Oncology and Carcinogenesis
Abstract

Despite a remarkable increase in the genomic profiling of cancer, integration of genomic discoveries into clinical care has lagged behind. We report the feasibility of rapid identification of targetable mutations in 153 pediatric patients with relapsed/refractory or high-risk leukemias enrolled on a prospective clinical trial conducted by the LEAP Consortium. Eighteen percent of patients had a high confidence Tier 1 or 2 recommendation. We describe clinical responses in the 14% of patients with relapsed/refractory leukemia who received the matched targeted therapy. Further, in order to inform future targeted therapy for patients, we validated variants of uncertain significance, performed ex vivo drug-sensitivity testing in patient leukemia samples, and identified new combinations of targeted therapies in cell lines and patient-derived xenograft models. These data and our collaborative approach should inform the design of future precision medicine trials. SIGNIFICANCE: Patients with relapsed/refractory leukemias face limited treatment options. Systematic integration of precision medicine efforts can inform therapy. We report the feasibility of identifying targetable mutations in children with leukemia and describe correlative biology studies validating therapeutic hypotheses and novel mutations.See related commentary by Bornhauser and Bourquin, p. 1322.This article is highlighted in the In This Issue feature, p. 1307.

Published
2021

3. P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia

Author

Lin, Kevin H., Rutter, Justine C., Xie, Abigail, Killarney, Shane T., Vaganay, Camille, Benaksas, Chaima, Ling, Frank, Sodaro, Gaetano, Meslin, Paul-Arthur, Bassil, Christopher F., Fenouille, Nina, Hoj, Jacob, Washart, Rachel, Ang, Hazel X., Cerda-Smith, Christian, Chaintreuil, Paul, Jacquel, Arnaud, Auberger, Patrick, Forget, Antoine, Itzykson, Raphael, Lu, Min, Lin, Jiaxing, Pierobon, Mariaelena, Sheng, Zhecheng, Li, Xinghai, Chilkoti, Ashutosh, Owzar, Kouros, Rizzieri, David A., Pardee, Timothy S., Benajiba, Lina, Petricoin, Emanuel, Puissant, Alexandre, and Wood, Kris C.

Published
2022
Full Text
View/download PDF

4. Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia

Author

Pardieu, Bryann, Pasanisi, Justine, Ling, Frank, Dal Bello, Reinaldo, Penneroux, Justine, Su, Angela, Joudinaud, Romane, Chat, Laureen, Wu, Hsin Chieh, Duchmann, Matthieu, Sodaro, Gaetano, Chauvel, Clémentine, Castelli, Florence A., Vasseur, Loic, Pacchiardi, Kim, Belloucif, Yannis, Laiguillon, Marie-Charlotte, Meduri, Eshwar, Vaganay, Camille, Alexe, Gabriela, Berrou, Jeannig, Benaksas, Chaima, Forget, Antoine, Braun, Thorsten, Gardin, Claude, Raffoux, Emmanuel, Clappier, Emmanuelle, Adès, Lionel, de Thé, Hugues, Fenaille, François, Huntly, Brian J., Stegmaier, Kimberly, Dombret, Hervé, Fenouille, Nina, Lobry, Camille, Puissant, Alexandre, and Itzykson, Raphael

Published
2022
Full Text
View/download PDF

7. Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML

Author

Duchmann, Matthieu, Joudinaud, Romane, Boudry, Augustin, Pasanisi, Justine, Di Feo, Giuseppe, Kim, Rathana, Bucci, Maxime, Chauvel, Clémentine, Chat, Laureen, Larcher, Lise, Pacchiardi, Kim, Mathis, Stéphanie, Raffoux, Emmanuel, Adès, Lionel, Berthon, Céline, Clappier, Emmanuelle, Roumier, Christophe, Puissant, Alexandre, Preudhomme, Claude, Duployez, Nicolas, and Itzykson, Raphaël

Published
2022
Full Text
View/download PDF

8. A multiparametric niche-like drug screening platform in acute myeloid leukemia

Author

Dal Bello, Reinaldo, Pasanisi, Justine, Joudinaud, Romane, Duchmann, Matthieu, Pardieu, Bryann, Ayaka, Paolo, Di Feo, Giuseppe, Sodaro, Gaetano, Chauvel, Clémentine, Kim, Rathana, Vasseur, Loic, Chat, Laureen, Ling, Frank, Pacchiardi, Kim, Vaganay, Camille, Berrou, Jeannig, Benaksas, Chaima, Boissel, Nicolas, Braun, Thorsten, Preudhomme, Claude, Dombret, Hervé, Raffoux, Emmanuel, Fenouille, Nina, Clappier, Emmanuelle, Adès, Lionel, Puissant, Alexandre, and Itzykson, Raphael

Published
2022
Full Text
View/download PDF

9. Tumor Lysis Syndrome and AKI: Beyond Crystal Mechanisms

Author

Arnaud, Marine, Loiselle, Maud, Vaganay, Camille, Pons, Stéphanie, Letavernier, Emmanuel, Demonchy, Jordane, Fodil, Sofiane, Nouacer, Manal, Placier, Sandrine, Frère, Perrine, Arrii, Eden, Lion, Julien, Mooney, Nuala, Itzykson, Raphael, Djediat, Chakib, Puissant, Alexandre, and Zafrani, Lara

Published
2022
Full Text
View/download PDF

10. Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer

Author

Lin, Kevin H., Rutter, Justine C., Xie, Abigail, Pardieu, Bryann, Winn, Emily T., Bello, Reinaldo Dal, Forget, Antoine, Itzykson, Raphael, Ahn, Yeong-Ran, Dai, Ziwei, Sobhan, Raiyan T., Anderson, Gray R., Singleton, Katherine R., Decker, Amy E., Winter, Peter S., Locasale, Jason W., Crawford, Lorin, Puissant, Alexandre, and Wood, Kris C.

Published
2020
Full Text
View/download PDF

12. Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

Author

Puissant, Alexandre, Frumm, Stacey M, Alexe, Gabriela, Bassil, Christopher F, Qi, Jun, Chanthery, Yvan H, Nekritz, Erin A, Zeid, Rhamy, Gustafson, William Clay, Greninger, Patricia, Garnett, Matthew J, McDermott, Ultan, Benes, Cyril H, Kung, Andrew L, Weiss, William A, Bradner, James E, and Stegmaier, Kimberly

Subjects
Human Genome, Pediatric Research Initiative, Genetics, Pediatric Cancer, Clinical Research, Pediatric, Neuroblastoma, Neurosciences, Rare Diseases, Cancer, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Animals, Apoptosis, Azepines, Cell Cycle Checkpoints, Cell Cycle Proteins, Cell Growth Processes, Cell Line, Tumor, Child, Down-Regulation, Female, Gene Amplification, Humans, Mice, Molecular Targeted Therapy, N-Myc Proto-Oncogene Protein, Nuclear Proteins, Oncogene Proteins, Promoter Regions, Genetic, Protein Structure, Tertiary, Proto-Oncogene Proteins c-myc, RNA, Small Interfering, Transcription Factors, Transfection, Triazoles, Xenograft Model Antitumor Assays, Oncology and Carcinogenesis
Abstract

Bromodomain inhibition comprises a promising therapeutic strategy in cancer, particularly for hematologic malignancies. To date, however, genomic biomarkers to direct clinical translation have been lacking. We conducted a cell-based screen of genetically defined cancer cell lines using a prototypical inhibitor of BET bromodomains. Integration of genetic features with chemosensitivity data revealed a robust correlation between MYCN amplification and sensitivity to bromodomain inhibition. We characterized the mechanistic and translational significance of this finding in neuroblastoma, a childhood cancer with frequent amplification of MYCN. Genome-wide expression analysis showed downregulation of the MYCN transcriptional program accompanied by suppression of MYCN transcription. Functionally, bromodomain-mediated inhibition of MYCN impaired growth and induced apoptosis in neuroblastoma. BRD4 knockdown phenocopied these effects, establishing BET bromodomains as transcriptional regulators of MYCN. BET inhibition conferred a significant survival advantage in 3 in vivo neuroblastoma models, providing a compelling rationale for developing BET bromodomain inhibitors in patients with neuroblastoma.

Published
2013

13. RETRACTED ARTICLE: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML

Author

Dubois, Alix, Furstoss, Nathan, Calleja, Anne, Zerhouni, Marwa, Cluzeau, Thomas, Savy, Coline, Marchetti, Sandrine, Hamouda, Mohamed Amine, Boulakirba, Sonia, Orange, François, Lacas-Gervais, Sandra, Karsenti, Jean-Michel, Mounier, Nicolas, Tamburini, Jérôme, Puissant, Alexandre, Luciano, Frederic, Jacquel, Arnaud, Auberger, Patrick, and Robert, Guillaume

Published
2019
Full Text
View/download PDF

16. Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia

Author

Ali, Ashfaq, Penneroux, Justine, Dal Bello, Jr, Reinaldo, Massé, Aline, Quentin, Samuel, Unnikrishnan, Ashwin, Hernandez, Lucie, Raffoux, Emmanuel, Ben Abdelali, Raouf, Renneville, Aline, Preudhomme, Claude, Pimanda, John, Dombret, Hervé, Soulier, Jean, Fenaux, Pierre, Clappier, Emmanuelle, Adès, Lionel, Puissant, Alexandre, and Itzykson, Raphael

Published
2018
Full Text
View/download PDF

17. Figure S1 from The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

Author

Su, Angela, primary, Ling, Frank, primary, Vaganay, Camille, primary, Sodaro, Gaetano, primary, Benaksas, Chaïma, primary, Dal Bello, Reinaldo, primary, Forget, Antoine, primary, Pardieu, Bryann, primary, Lin, Kevin H., primary, Rutter, Justine C., primary, Bassil, Christopher F., primary, Fortin, Gael, primary, Pasanisi, Justine, primary, Antony-Debré, Iléana, primary, Alexe, Gabriela, primary, Benoist, Jean-François, primary, Pruvost, Alain, primary, Pikman, Yana, primary, Qi, Jun, primary, Schlageter, Marie-Hélène, primary, Micol, Jean-Baptiste, primary, Roti, Giovanni, primary, Cluzeau, Thomas, primary, Dombret, Hervé, primary, Preudhomme, Claude, primary, Fenouille, Nina, primary, Benajiba, Lina, primary, Golan, Hava M., primary, Stegmaier, Kimberly, primary, Lobry, Camille, primary, Wood, Kris C., primary, Itzykson, Raphael, primary, and Puissant, Alexandre, primary

Published
2023
Full Text
View/download PDF

18. Table S6 from The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

Author

Su, Angela, primary, Ling, Frank, primary, Vaganay, Camille, primary, Sodaro, Gaetano, primary, Benaksas, Chaïma, primary, Dal Bello, Reinaldo, primary, Forget, Antoine, primary, Pardieu, Bryann, primary, Lin, Kevin H., primary, Rutter, Justine C., primary, Bassil, Christopher F., primary, Fortin, Gael, primary, Pasanisi, Justine, primary, Antony-Debré, Iléana, primary, Alexe, Gabriela, primary, Benoist, Jean-François, primary, Pruvost, Alain, primary, Pikman, Yana, primary, Qi, Jun, primary, Schlageter, Marie-Hélène, primary, Micol, Jean-Baptiste, primary, Roti, Giovanni, primary, Cluzeau, Thomas, primary, Dombret, Hervé, primary, Preudhomme, Claude, primary, Fenouille, Nina, primary, Benajiba, Lina, primary, Golan, Hava M., primary, Stegmaier, Kimberly, primary, Lobry, Camille, primary, Wood, Kris C., primary, Itzykson, Raphael, primary, and Puissant, Alexandre, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Data from Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium

Author

Pikman, Yana, primary, Tasian, Sarah K., primary, Sulis, Maria Luisa, primary, Stevenson, Kristen, primary, Blonquist, Traci M., primary, Apsel Winger, Beth, primary, Cooper, Todd M., primary, Pauly, Melinda, primary, Maloney, Kelly W., primary, Burke, Michael J., primary, Brown, Patrick A., primary, Gossai, Nathan, primary, McNeer, Jennifer L., primary, Shukla, Neerav N., primary, Cole, Peter D., primary, Kahn, Justine M., primary, Chen, Jing, primary, Barth, Matthew J., primary, Magee, Jeffrey A., primary, Gennarini, Lisa, primary, Adhav, Asmani A., primary, Clinton, Catherine M., primary, Ocasio-Martinez, Nicole, primary, Gotti, Giacomo, primary, Li, Yuting, primary, Lin, Shan, primary, Imamovic, Alma, primary, Tognon, Cristina E., primary, Patel, Tasleema, primary, Faust, Haley L., primary, Contreras, Cristina F., primary, Cremer, Anjali, primary, Cortopassi, Wilian A., primary, Garrido Ruiz, Diego, primary, Jacobson, Matthew P., primary, Dharia, Neekesh V., primary, Su, Angela, primary, Robichaud, Amanda L., primary, Saur Conway, Amy, primary, Tarlock, Katherine, primary, Stieglitz, Elliot, primary, Place, Andrew E., primary, Puissant, Alexandre, primary, Hunger, Stephen P., primary, Kim, Annette S., primary, Lindeman, Neal I., primary, Gore, Lia, primary, Janeway, Katherine A., primary, Silverman, Lewis B., primary, Tyner, Jeffrey W., primary, Harris, Marian H., primary, Loh, Mignon L., primary, and Stegmaier, Kimberly, primary

Published
2023
Full Text
View/download PDF

20. Data from Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium

Author

Pikman, Yana, primary, Tasian, Sarah K., primary, Sulis, Maria Luisa, primary, Stevenson, Kristen, primary, Blonquist, Traci M., primary, Apsel Winger, Beth, primary, Cooper, Todd M., primary, Pauly, Melinda, primary, Maloney, Kelly W., primary, Burke, Michael J., primary, Brown, Patrick A., primary, Gossai, Nathan, primary, McNeer, Jennifer L., primary, Shukla, Neerav N., primary, Cole, Peter D., primary, Kahn, Justine M., primary, Chen, Jing, primary, Barth, Matthew J., primary, Magee, Jeffrey A., primary, Gennarini, Lisa, primary, Adhav, Asmani A., primary, Clinton, Catherine M., primary, Ocasio-Martinez, Nicole, primary, Gotti, Giacomo, primary, Li, Yuting, primary, Lin, Shan, primary, Imamovic, Alma, primary, Tognon, Cristina E., primary, Patel, Tasleema, primary, Faust, Haley L., primary, Contreras, Cristina F., primary, Cremer, Anjali, primary, Cortopassi, Wilian A., primary, Garrido Ruiz, Diego, primary, Jacobson, Matthew P., primary, Dharia, Neekesh V., primary, Su, Angela, primary, Robichaud, Amanda L., primary, Saur Conway, Amy, primary, Tarlock, Katherine, primary, Stieglitz, Elliot, primary, Place, Andrew E., primary, Puissant, Alexandre, primary, Hunger, Stephen P., primary, Kim, Annette S., primary, Lindeman, Neal I., primary, Gore, Lia, primary, Janeway, Katherine A., primary, Silverman, Lewis B., primary, Tyner, Jeffrey W., primary, Harris, Marian H., primary, Loh, Mignon L., primary, and Stegmaier, Kimberly, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Data from The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

Author

Su, Angela, primary, Ling, Frank, primary, Vaganay, Camille, primary, Sodaro, Gaetano, primary, Benaksas, Chaïma, primary, Dal Bello, Reinaldo, primary, Forget, Antoine, primary, Pardieu, Bryann, primary, Lin, Kevin H., primary, Rutter, Justine C., primary, Bassil, Christopher F., primary, Fortin, Gael, primary, Pasanisi, Justine, primary, Antony-Debré, Iléana, primary, Alexe, Gabriela, primary, Benoist, Jean-François, primary, Pruvost, Alain, primary, Pikman, Yana, primary, Qi, Jun, primary, Schlageter, Marie-Hélène, primary, Micol, Jean-Baptiste, primary, Roti, Giovanni, primary, Cluzeau, Thomas, primary, Dombret, Hervé, primary, Preudhomme, Claude, primary, Fenouille, Nina, primary, Benajiba, Lina, primary, Golan, Hava M., primary, Stegmaier, Kimberly, primary, Lobry, Camille, primary, Wood, Kris C., primary, Itzykson, Raphael, primary, and Puissant, Alexandre, primary

Published
2023
Full Text
View/download PDF

22. Figure S5 from Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium

Author

Pikman, Yana, primary, Tasian, Sarah K., primary, Sulis, Maria Luisa, primary, Stevenson, Kristen, primary, Blonquist, Traci M., primary, Apsel Winger, Beth, primary, Cooper, Todd M., primary, Pauly, Melinda, primary, Maloney, Kelly W., primary, Burke, Michael J., primary, Brown, Patrick A., primary, Gossai, Nathan, primary, McNeer, Jennifer L., primary, Shukla, Neerav N., primary, Cole, Peter D., primary, Kahn, Justine M., primary, Chen, Jing, primary, Barth, Matthew J., primary, Magee, Jeffrey A., primary, Gennarini, Lisa, primary, Adhav, Asmani A., primary, Clinton, Catherine M., primary, Ocasio-Martinez, Nicole, primary, Gotti, Giacomo, primary, Li, Yuting, primary, Lin, Shan, primary, Imamovic, Alma, primary, Tognon, Cristina E., primary, Patel, Tasleema, primary, Faust, Haley L., primary, Contreras, Cristina F., primary, Cremer, Anjali, primary, Cortopassi, Wilian A., primary, Garrido Ruiz, Diego, primary, Jacobson, Matthew P., primary, Dharia, Neekesh V., primary, Su, Angela, primary, Robichaud, Amanda L., primary, Saur Conway, Amy, primary, Tarlock, Katherine, primary, Stieglitz, Elliot, primary, Place, Andrew E., primary, Puissant, Alexandre, primary, Hunger, Stephen P., primary, Kim, Annette S., primary, Lindeman, Neal I., primary, Gore, Lia, primary, Janeway, Katherine A., primary, Silverman, Lewis B., primary, Tyner, Jeffrey W., primary, Harris, Marian H., primary, Loh, Mignon L., primary, and Stegmaier, Kimberly, primary

Published
2023
Full Text
View/download PDF

23. Table S1 from Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium

Author

Pikman, Yana, primary, Tasian, Sarah K., primary, Sulis, Maria Luisa, primary, Stevenson, Kristen, primary, Blonquist, Traci M., primary, Apsel Winger, Beth, primary, Cooper, Todd M., primary, Pauly, Melinda, primary, Maloney, Kelly W., primary, Burke, Michael J., primary, Brown, Patrick A., primary, Gossai, Nathan, primary, McNeer, Jennifer L., primary, Shukla, Neerav N., primary, Cole, Peter D., primary, Kahn, Justine M., primary, Chen, Jing, primary, Barth, Matthew J., primary, Magee, Jeffrey A., primary, Gennarini, Lisa, primary, Adhav, Asmani A., primary, Clinton, Catherine M., primary, Ocasio-Martinez, Nicole, primary, Gotti, Giacomo, primary, Li, Yuting, primary, Lin, Shan, primary, Imamovic, Alma, primary, Tognon, Cristina E., primary, Patel, Tasleema, primary, Faust, Haley L., primary, Contreras, Cristina F., primary, Cremer, Anjali, primary, Cortopassi, Wilian A., primary, Garrido Ruiz, Diego, primary, Jacobson, Matthew P., primary, Dharia, Neekesh V., primary, Su, Angela, primary, Robichaud, Amanda L., primary, Saur Conway, Amy, primary, Tarlock, Katherine, primary, Stieglitz, Elliot, primary, Place, Andrew E., primary, Puissant, Alexandre, primary, Hunger, Stephen P., primary, Kim, Annette S., primary, Lindeman, Neal I., primary, Gore, Lia, primary, Janeway, Katherine A., primary, Silverman, Lewis B., primary, Tyner, Jeffrey W., primary, Harris, Marian H., primary, Loh, Mignon L., primary, and Stegmaier, Kimberly, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Tables 1 - 9 from Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

Author

Puissant, Alexandre, primary, Frumm, Stacey M., primary, Alexe, Gabriela, primary, Bassil, Christopher F., primary, Qi, Jun, primary, Chanthery, Yvan H., primary, Nekritz, Erin A., primary, Zeid, Rhamy, primary, Gustafson, William Clay, primary, Greninger, Patricia, primary, Garnett, Matthew J., primary, McDermott, Ultan, primary, Benes, Cyril H., primary, Kung, Andrew L., primary, Weiss, William A., primary, Bradner, James E., primary, and Stegmaier, Kimberly, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Methods from Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium

Author

Pikman, Yana, primary, Tasian, Sarah K., primary, Sulis, Maria Luisa, primary, Stevenson, Kristen, primary, Blonquist, Traci M., primary, Apsel Winger, Beth, primary, Cooper, Todd M., primary, Pauly, Melinda, primary, Maloney, Kelly W., primary, Burke, Michael J., primary, Brown, Patrick A., primary, Gossai, Nathan, primary, McNeer, Jennifer L., primary, Shukla, Neerav N., primary, Cole, Peter D., primary, Kahn, Justine M., primary, Chen, Jing, primary, Barth, Matthew J., primary, Magee, Jeffrey A., primary, Gennarini, Lisa, primary, Adhav, Asmani A., primary, Clinton, Catherine M., primary, Ocasio-Martinez, Nicole, primary, Gotti, Giacomo, primary, Li, Yuting, primary, Lin, Shan, primary, Imamovic, Alma, primary, Tognon, Cristina E., primary, Patel, Tasleema, primary, Faust, Haley L., primary, Contreras, Cristina F., primary, Cremer, Anjali, primary, Cortopassi, Wilian A., primary, Garrido Ruiz, Diego, primary, Jacobson, Matthew P., primary, Dharia, Neekesh V., primary, Su, Angela, primary, Robichaud, Amanda L., primary, Saur Conway, Amy, primary, Tarlock, Katherine, primary, Stieglitz, Elliot, primary, Place, Andrew E., primary, Puissant, Alexandre, primary, Hunger, Stephen P., primary, Kim, Annette S., primary, Lindeman, Neal I., primary, Gore, Lia, primary, Janeway, Katherine A., primary, Silverman, Lewis B., primary, Tyner, Jeffrey W., primary, Harris, Marian H., primary, Loh, Mignon L., primary, and Stegmaier, Kimberly, primary

Published
2023
Full Text
View/download PDF

26. Data from The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

Author

Su, Angela, primary, Ling, Frank, primary, Vaganay, Camille, primary, Sodaro, Gaetano, primary, Benaksas, Chaïma, primary, Dal Bello, Reinaldo, primary, Forget, Antoine, primary, Pardieu, Bryann, primary, Lin, Kevin H., primary, Rutter, Justine C., primary, Bassil, Christopher F., primary, Fortin, Gael, primary, Pasanisi, Justine, primary, Antony-Debré, Iléana, primary, Alexe, Gabriela, primary, Benoist, Jean-François, primary, Pruvost, Alain, primary, Pikman, Yana, primary, Qi, Jun, primary, Schlageter, Marie-Hélène, primary, Micol, Jean-Baptiste, primary, Roti, Giovanni, primary, Cluzeau, Thomas, primary, Dombret, Hervé, primary, Preudhomme, Claude, primary, Fenouille, Nina, primary, Benajiba, Lina, primary, Golan, Hava M., primary, Stegmaier, Kimberly, primary, Lobry, Camille, primary, Wood, Kris C., primary, Itzykson, Raphael, primary, and Puissant, Alexandre, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figures 1 -11 from Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

Author

Puissant, Alexandre, primary, Frumm, Stacey M., primary, Alexe, Gabriela, primary, Bassil, Christopher F., primary, Qi, Jun, primary, Chanthery, Yvan H., primary, Nekritz, Erin A., primary, Zeid, Rhamy, primary, Gustafson, William Clay, primary, Greninger, Patricia, primary, Garnett, Matthew J., primary, McDermott, Ultan, primary, Benes, Cyril H., primary, Kung, Andrew L., primary, Weiss, William A., primary, Bradner, James E., primary, and Stegmaier, Kimberly, primary

Published
2023
Full Text
View/download PDF

28. Data from Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

Author

Puissant, Alexandre, primary, Frumm, Stacey M., primary, Alexe, Gabriela, primary, Bassil, Christopher F., primary, Qi, Jun, primary, Chanthery, Yvan H., primary, Nekritz, Erin A., primary, Zeid, Rhamy, primary, Gustafson, William Clay, primary, Greninger, Patricia, primary, Garnett, Matthew J., primary, McDermott, Ultan, primary, Benes, Cyril H., primary, Kung, Andrew L., primary, Weiss, William A., primary, Bradner, James E., primary, and Stegmaier, Kimberly, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure Legend from Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

Author

Puissant, Alexandre, primary, Frumm, Stacey M., primary, Alexe, Gabriela, primary, Bassil, Christopher F., primary, Qi, Jun, primary, Chanthery, Yvan H., primary, Nekritz, Erin A., primary, Zeid, Rhamy, primary, Gustafson, William Clay, primary, Greninger, Patricia, primary, Garnett, Matthew J., primary, McDermott, Ultan, primary, Benes, Cyril H., primary, Kung, Andrew L., primary, Weiss, William A., primary, Bradner, James E., primary, and Stegmaier, Kimberly, primary

Published
2023
Full Text
View/download PDF

30. Exploiting an Asp-Glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia

Author

Wagner, Florence F., Benajiba, Lina, Campbell, Arthur J., Weïwer, Michel, Sacher, Joshua R., Gale, Jennifer P., Ross, Linda, Puissant, Alexandre, Alexe, Gabriela, Conway, Amy, Back, Morgan, Pikman, Yana, Galinsky, Ilene, DeAngelo, Daniel J., Stone, Richard M., Kaya, Taner, Shi, Xi, Robers, Matthew B., Machleidt, Thomas, Wilkinson, Jennifer, Hermine, Olivier, Kung, Andrew, Stein, Adam J., Lakshminarasimhan, Damodharan, Hemann, Michael T., Scolnick, Edward, Zhang, Yan-Ling, Pan, Jen Q., Stegmaier, Kimberly, and Holson, Edward B.

Published
2018
Full Text
View/download PDF

31. Supplemental Figure 1 from Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors

Author

Grosso, Sébastien, primary, Puissant, Alexandre, primary, Dufies, Maeva, primary, Colosetti, Pascal, primary, Jacquel, Arnaud, primary, Lebrigand, Kevin, primary, Barbry, Pascal, primary, Deckert, Marcel, primary, Cassuto, Jill Patrice, primary, Mari, Bernard, primary, and Auberger, Patrick, primary

Published
2023
Full Text
View/download PDF

32. Supplemental Table 1 from Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors

Author

Grosso, Sébastien, primary, Puissant, Alexandre, primary, Dufies, Maeva, primary, Colosetti, Pascal, primary, Jacquel, Arnaud, primary, Lebrigand, Kevin, primary, Barbry, Pascal, primary, Deckert, Marcel, primary, Cassuto, Jill Patrice, primary, Mari, Bernard, primary, and Auberger, Patrick, primary

Published
2023
Full Text
View/download PDF

34. Data from Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC

Author

Fenouille, Nina, primary, Puissant, Alexandre, primary, Dufies, Maeva, primary, Robert, Guillaume, primary, Jacquel, Arnaud, primary, Ohanna, Mickaël, primary, Deckert, Marcel, primary, Pasquet, Jean-Max, primary, Mahon, François-Xavier, primary, Cassuto, Jill-Patrice, primary, Raynaud, Sophie, primary, Tartare-Deckert, Sophie, primary, and Auberger, Patrick, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figures 1-6 from Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC

Author

Fenouille, Nina, primary, Puissant, Alexandre, primary, Dufies, Maeva, primary, Robert, Guillaume, primary, Jacquel, Arnaud, primary, Ohanna, Mickaël, primary, Deckert, Marcel, primary, Pasquet, Jean-Max, primary, Mahon, François-Xavier, primary, Cassuto, Jill-Patrice, primary, Raynaud, Sophie, primary, Tartare-Deckert, Sophie, primary, and Auberger, Patrick, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Methods from Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC

Author

Fenouille, Nina, primary, Puissant, Alexandre, primary, Dufies, Maeva, primary, Robert, Guillaume, primary, Jacquel, Arnaud, primary, Ohanna, Mickaël, primary, Deckert, Marcel, primary, Pasquet, Jean-Max, primary, Mahon, François-Xavier, primary, Cassuto, Jill-Patrice, primary, Raynaud, Sophie, primary, Tartare-Deckert, Sophie, primary, and Auberger, Patrick, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure Legends 1-6 from Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC

Author

Fenouille, Nina, primary, Puissant, Alexandre, primary, Dufies, Maeva, primary, Robert, Guillaume, primary, Jacquel, Arnaud, primary, Ohanna, Mickaël, primary, Deckert, Marcel, primary, Pasquet, Jean-Max, primary, Mahon, François-Xavier, primary, Cassuto, Jill-Patrice, primary, Raynaud, Sophie, primary, Tartare-Deckert, Sophie, primary, and Auberger, Patrick, primary

Published
2023
Full Text
View/download PDF

44. Favorable pharmacokinetics and pharmacodynamics properties of Gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukaemia FLT3-ITD patients

Author

Vignal, Nicolas, primary, Kelly, Loïs, additional, Lengline, Etienne, additional, Cabannes-Hamy, Aurélie, additional, Siavellis, Justine, additional, Ghez, David, additional, Sauvageon, Hélène, additional, Braun, Thorsten, additional, Jacqz-Aigrain, Evelyne, additional, Kohn, Milena, additional, Rousselot, Philippe, additional, Puissant, Alexandre, additional, Raffoux, Emmanuel, additional, Mourah, Samia, additional, and Goldwirt, Lauriane, additional

Published
2023
Full Text
View/download PDF

45. MCB-613 exploits a collateral sensitivity in drug resistantEGFR-mutant non-small cell lung cancer through covalent inhibition of KEAP1

Author

Bassil, Christopher F., primary, Anderson, Gray R., additional, Mayro, Benjamin, additional, Askin, Kayleigh N., additional, Winter, Peter S., additional, Gruber, Samuel, additional, Hall, Tierney M., additional, Hoj, Jacob P., additional, Cerda-Smith, Christian, additional, Hutchinson, Haley M., additional, Killarney, Shane T., additional, Singleton, Katherine R., additional, Qin, Li, additional, Jubien-Girard, Kévin, additional, Favreau, Cécile, additional, Martin, Anthony R., additional, Robert, Guillaume, additional, Benhida, Rachid, additional, Auberger, Patrick, additional, Pendergast, Ann Marie, additional, Lonard, David M., additional, Puissant, Alexandre, additional, and Wood, Kris C., additional

Published
2023
Full Text
View/download PDF

46. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia

Author

Fenouille, Nina, Bassil, Christopher F, Ben-Sahra, Issam, Benajiba, Lina, Alexe, Gabriela, Ramos, Azucena, Pikman, Yana, Conway, Amy S, Burgess, Michael R, Li, Qing, Luciano, Frédéric, Auberger, Patrick, Galinsky, Ilene, DeAngelo, Daniel J, Stone, Richard M, Zhang, Yi, Perkins, Archibald S, Shannon, Kevin, Hemann, Michael T, Puissant, Alexandre, and Stegmaier, Kimberly

Subjects
Oncogenes -- Health aspects, Cell metabolism -- Genetic aspects -- Health aspects, Gene expression -- Health aspects, Acute myelocytic leukemia -- Physiological aspects -- Analysis -- Genetic aspects -- Development and progression -- Care and treatment, Biological sciences, Health
Abstract

Expression of the MECOM (also known as EVI1) proto-oncogene is deregulated by chromosomal translocations in some cases of acute myeloid leukemia (AML) and is associated with poor clinical outcome. Here, through transcriptomic and metabolomic profiling of hematopoietic cells, we reveal that EVI1 overexpression alters cellular metabolism. A screen using pooled short hairpin RNAs (shRNAs) identified the ATP-buffering, mitochondrial creatine kinase CKMT1 as necessary for survival of EVI1-expressing cells in subjects with EVI1-positive AML. EVI1 promotes CKMT1 expression by repressing the myeloid differentiation regulator RUNX1. Suppression of arginine-creatine metabolism by CKMT1-directed shRNAs or by the small molecule cyclocreatine selectively decreased the viability, promoted the cell cycle arrest and apoptosis of human EVI1-positive cell lines, and prolonged survival in both orthotopic xenograft models and mouse models of primary AML. CKMT1 inhibition altered mitochondrial respiration and ATP production, an effect that was abrogated by phosphocreatine-mediated reactivation of the arginine-creatine pathway. Targeting CKMT1 is thus a promising therapeutic strategy for this EVI1-driven AML subtype that is highly resistant to current treatment regimens., Author(s): Nina Fenouille [1]; Christopher F Bassil [2]; Issam Ben-Sahra [3]; Lina Benajiba [2]; Gabriela Alexe [2, 4, 5]; Azucena Ramos [1]; Yana Pikman [2]; Amy S Conway [2]; Michael [...]

Published
2017
Full Text
View/download PDF

47. Retraction Note: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML

Author

Dubois, Alix, Furstoss, Nathan, Calleja, Anne, Zerhouni, Marwa, Cluzeau, Thomas, Savy, Coline, Marchetti, Sandrine, Hamouda, Mohamed Amine, Boulakirba, Sonia, Orange, François, Lacas-Gervais, Sandra, Karsenti, Jean-Michel, Mounier, Nicolas, Tamburini, Jérôme, Puissant, Alexandre, Luciano, Frederic, Jacquel, Arnaud, Auberger, Patrick, and Robert, Guillaume

Published
2020
Full Text
View/download PDF

48. Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively

Author

Dal Bello, Reinaldo, primary, Pacchiardi, Kim, additional, Chauvel, Clémentine, additional, Adès, Lionel, additional, Braun, Thorsten, additional, Pasanisi, Justine, additional, Fournier, Elise, additional, Berthon, Céline, additional, Clappier, Emmanuelle, additional, Raffoux, Emmanuel, additional, Lebon, Delphine, additional, Cluzeau, Thomas, additional, Roumier, Christophe, additional, Plesa, Adriana, additional, Celli-Lebras, Karine, additional, Dombret, Hervé, additional, Preudhomme, Claude, additional, Mathis, Stéphanie, additional, Puissant, Alexandre, additional, Gardin, Claude, additional, and Itzykson, Raphael, additional

Published
2022
Full Text
View/download PDF

49. JAK Inhibition Mediates Clonal Selection of RAS Pathway Mutations in Myeloproliferative Neoplasms

Author

Maslah, Nabih, primary, Roux, Blandine, additional, Kaci, Nina, additional, Verger, Emmanuelle, additional, Daltro De Oliveira, Rafael, additional, Pasquer, Hélène, additional, Gauthier, Nicolas, additional, Soret, Juliette, additional, Ganesan, Saravanan, additional, Gou, Panhong, additional, Ling, Frank, additional, Parquet, Nathalie, additional, Vainchenker, William, additional, Raffoux, Emmanuel, additional, Padua, Rose Ann, additional, Giraudier, Stephane, additional, Puissant, Alexandre, additional, Lobry, Camille, additional, Kiladjian, Jean-Jacques, additional, Cassinat, Bruno, additional, and Benajiba, Lina, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results